Literature DB >> 25348051

[Sepsis-associated Purpura Fulminans International Registry--Europe (SAPFIRE)].

F M Brunkhorst1, V Patchev.   

Abstract

BACKGROUND: Purpura fulminans is a rare life-threatening condition which is characterized by disseminated thrombosis in dermal and systemic microcirculation, cutaneous hemorrhages with progressing necrosis and multiple organ failure. The underlying pathogenesis is based on the disruption of the intrinsic anticoagulation cascade, with protein C deficiency being considered the leading factor in this process. In the majority of cases, the condition emerges as consumptive coagulopathy associated with severe sepsis.
OBJECTIVES: Epidemiological data on sepsis-associated purpura fulminans (SAPF) are scarce and evidence-based treatment guidelines have not been established yet. While restoration of the balance in the coagulation cascade is a declared therapeutic goal, evaluations of the efficacy of different therapeutic approaches in randomized clinical trials are still lacking. The causal role of individual microbial pathogens also requires comprehensive evaluation.
METHODS: A prospective multicenter Sepsis-Associated Purpura Fulminans International Registry-Europe (SAPFIRE) will be established in the first quarter of 2015. For the first time, participating centers will systematically collect information on etiology, clinical course, biomarkers, treatment, morbidity, and mortality of SAPF.
RESULTS: The SAPFIRE data will be periodically evaluated and disseminated. Retrospective analysis of each center's data and regular access to aggregated information collected by other centers will enable the participants to monitor and update care quality standards.

Entities:  

Mesh:

Year:  2014        PMID: 25348051     DOI: 10.1007/s00063-014-0402-z

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  41 in total

1.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.

Authors:  B White; W Livingstone; C Murphy; A Hodgson; M Rafferty; O P Smith
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  Diagnosis and management of neonatal purpura fulminans.

Authors:  V E Price; D L Ledingham; A Krümpel; A K Chan
Journal:  Semin Fetal Neonatal Med       Date:  2011-08-11       Impact factor: 3.926

Review 3.  Acquired purpura fulminans.

Authors:  R B Francis
Journal:  Semin Thromb Hemost       Date:  1990-10       Impact factor: 4.180

4.  Protein C substitution in sepsis-associated purpura fulminans.

Authors:  E Rintala; M Kauppila; O P Seppälä; L M Voipio-Pulkki; V Pettilä; V Rasi; P Kotilainen
Journal:  Crit Care Med       Date:  2000-07       Impact factor: 7.598

Review 5.  Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis.

Authors:  E Abraham
Journal:  Crit Care Med       Date:  2000-09       Impact factor: 7.598

Review 6.  Coagulopathy in malaria.

Authors:  Pantep Angchaisuksiri
Journal:  Thromb Res       Date:  2013-09-26       Impact factor: 3.944

7.  Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients.

Authors:  Alex Veldman; Doris Fischer; Flora Y Wong; Wolfhart Kreuz; Michael Sasse; Bruno Eberspächer; Ulrich Mansmann; Rudolf Schosser
Journal:  Crit Care       Date:  2010-08-19       Impact factor: 9.097

8.  Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

Authors:  Jean-Louis Vincent; Simon Nadel; Demetrios J Kutsogiannis; R T Noel Gibney; S Betty Yan; Virginia L Wyss; Joan E Bailey; Carol L Mitchell; Samiha Sarwat; Stephen M Shinall; Jonathan M Janes
Journal:  Crit Care       Date:  2005-05-17       Impact factor: 9.097

9.  The aPC treatment improves microcirculation in severe sepsis/septic shock syndrome.

Authors:  Abele Donati; Elisa Damiani; Laura Botticelli; Erica Adrario; Maria Rita Lombrano; Roberta Domizi; Benedetto Marini; Jurgen Wge Van Teeffelen; Paola Carletti; Massimo Girardis; Paolo Pelaia; Can Ince
Journal:  BMC Anesthesiol       Date:  2013-09-26       Impact factor: 2.217

10.  Improved survival of children with sepsis and purpura: effects of age, gender, and era.

Authors:  Martine Maat; Corinne M P Buysse; Marieke Emonts; Lodewijk Spanjaard; Koen F M Joosten; Ronald de Groot; Jan A Hazelzet
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  2 in total

1.  [Treatment failure after postinfectious purpura fulminans despite interdisciplinary surgical and intensive medical therapy].

Authors:  S A Alawi; R Ipaktchi; K Suchodolski; A Jokuszies
Journal:  Med Klin Intensivmed Notfmed       Date:  2020-02-13       Impact factor: 0.840

2.  Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial.

Authors:  Klaus Stahl; Philipp Wand; Christian Bode; Sascha David; Benjamin Seeliger; Pedro David Wendel-Garcia; Julius J Schmidt; Bernhard M W Schmidt; Andrea Sauer; Felix Lehmann; Ulrich Budde; Markus Busch; Olaf Wiesner; Tobias Welte; Hermann Haller; Heiner Wedemeyer; Christian Putensen; Marius M Hoeper
Journal:  Crit Care       Date:  2022-05-12       Impact factor: 19.334

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.